Skip to main content
SpringerLink
Log in

Psychotropic Drug-Induced Sexual Function Disorders

Diagnosis, Incidence and Management

  • Pharmacoepidemiology
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

The human sexual response can be divided into 3 phases: desire (libido), excitement (arousal) and orgasm. The fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) classifies sexual disorders into 4 categories: (i) primary; (ii) general medical condition-related; (iii) substance-induced; and (iv) ‘not otherwise specified’ sexual dysfunctions. Each of the 4 DSM-IV categories has disorders in all 3 sexual phases.

Substance-induced sexual dysfunctions are caused by the use of either substances of abuse [alcohol (ethanol), amphetamines, cocaine, opioids or sedatives/-hypnotics/anxiolytics], or prescription medications which include psychotropic drugs.

Patients with psychiatric difficulties tend to experience more frequent sexual function disturbances. The literature provides more than anecdotal evidence that psychotropic drugs can induce sexual function disorders in the epidemiologically vulnerable population of psychiatric patients.

Sexual dysfunctions caused by psychotropic drugs can be divided into 2 groups: sexual inhibition (inhibited desire, inhibited arousal and inhibited orgasm) and increased sexual function disorders (increased sexual desire, priapism and premature ejaculation).

The diagnosis of psychotropic drug-induced sexual function disorders is easy if the psychiatrist is sensitive to the existence of these adverse effects. This mostly involves careful history taking, although several questionnaires have been developed for reliable and valid quantification of sexual functioning. Diagnosis is usually established if the sexual function disorders develop when the patient is receiving a psychotropic drug and then disappear when the offending drug is discontinued.

The management of psychotropic-drug induced sexual inhibition can be divided into 6 steps: inform the patient about the possibility of sexual inhibition occurring before prescribing a psychotropic agent; wait for remission or tolerance of sexual inhibition; reduce the dosage of the psychotropic drug; switch the medication to one less likely to cause sexual inhibition; if possible, adjust the concomitant nonpsychotropic drugs; and add various pharmacological agents to the existing psychotropic drug to treat the sexual inhibition.

Physicians should take sexual histories as a routine practice when prescribing psychotropic drugs. Through careful management and patience on the part of both the patient and the physician, psychotropic drug-induced sexual function disorders can be improved so that the patient’s compliance with medication and quality of life can be optimised.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Masters WH, Johnson V. Human sexual response. Boston (MA): Little, Brown, and Co., 1966

    Google Scholar 

  2. Shen WW, Sata LS, Hofstatter L. Thioridazine and understanding sexual phases in both sexes. Psychiatry J Univ Ottawa 1984; 9: 187–9

    CAS  Google Scholar 

  3. Masters WH, Johnson V. Human sexual inadequacy. Boston (MA): Little, Brown, and Co., 1970

    Google Scholar 

  4. Kaplan HS. The classification of the female sexual dysfunctions. J Sex Marital Ther 1974; 1: 124–38

    Article  PubMed  CAS  Google Scholar 

  5. Kaplan HS. The new sex therapy: active treatment of sexual dysfunctions. New York (NY): Brunner/Mazel, 1974

    Google Scholar 

  6. Kaplan HS. Disorders of sexual desire and other new concepts and techniques in sex therapy. New York (NY): Brunner/Mazel, 1979

    Google Scholar 

  7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington (DC): American Psychiatric Association, 1987

    Google Scholar 

  8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Association, 1994

    Google Scholar 

  9. Shen WW, Sata LS. Inhibited female orgasm resulting from psychotropic drugs: a clinical review. J Reprod Med 1983; 28: 497–9

    PubMed  CAS  Google Scholar 

  10. Shen WW, Sata LS. Inhibited female orgasm resulting from psychotropic drugs: a five-year updated clinical review. J Reprod Med 1990; 35: 11–4

    PubMed  CAS  Google Scholar 

  11. Hsu JH, Shen WW. Male sexual side effects associated with antidepressants: a descriptive clinical study of 32 patients. Int J Psychiatry Med 1995; 25: 191–201

    Article  PubMed  CAS  Google Scholar 

  12. Shen WW, Hsu JH. Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. Int J Psychiatry Med 1995; 25: 239–48

    Article  PubMed  CAS  Google Scholar 

  13. Davidson JRT. Sexual dysfunction and antidepressants. Depression 1995; 2: 233–40

    Article  Google Scholar 

  14. Monteiro WO, Noshirvani HF, Marks IM, et al. Anorgasmia from clomipramine in obsessive-compulsive disorder: a controlled trial. Br J Psychiatry 1987; 151: 107–12

    Article  PubMed  CAS  Google Scholar 

  15. Harrison WM, Stewart J, Ehrhardt AA, et al. A controlled study of the effects of antidepressants on sexual function. Psychopharmacol Bull 1985; 21: 85–8

    PubMed  CAS  Google Scholar 

  16. Harrison WM, Rabkin JG, Ehrhardt AA, et al. Effects of antidepressant medication on sexual function: a controlled study. J Clin Psychopharmacol 1986; 6: 144–9

    Article  PubMed  CAS  Google Scholar 

  17. Solyom L, Solyom C, Ledwidge B. The fluoxetine treatment of low-weight, chronic bulimia nervosa. J Clin Psychopharmacol 1990; 10: 421–5

    Article  PubMed  CAS  Google Scholar 

  18. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side-effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scand 1987; 76 Suppl. 334: 1–99

    Article  Google Scholar 

  19. Aizenberg D, Zemishlany Z, Dorman-Etrog P, et al. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 1995; 56: 137–41

    PubMed  CAS  Google Scholar 

  20. Ghadirian AM, Annable L, Blanger M-C. Lithium, benzodiazepines and sexual function in bipolar patients. Am J Psychiatry 1992; 149: 801–5

    PubMed  CAS  Google Scholar 

  21. Kotin T, Wilbert DE, Verberg D, et al. Thioridazine and sexual dysfunction. Am J Psychiatry 1976; 133: 82–5

    PubMed  CAS  Google Scholar 

  22. Kowalski A, Stanley RO, Dennerstein L, et al. The sexual side effects of antidepressant medication: a double-blind comparison of two antidepressants in a non-psychiatric population. Br J Psychiatry 1985; 147: 413–8

    Article  PubMed  CAS  Google Scholar 

  23. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic treated schizophrenic outpatients. J Nerv Ment Dis 1982; 170: 463–7

    Article  PubMed  CAS  Google Scholar 

  24. Kline MD. Fluoxetine and anorgasmia [letter]. Am J Psychiatry 1989; 146: 804

    PubMed  CAS  Google Scholar 

  25. Herman JB, Brotman AW, Pollack MH, et al. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1990; 51: 25–7

    PubMed  CAS  Google Scholar 

  26. Musher JS. Anorgasmia with the use of fluoxetine [letter]. Am J Psychiatry 1990; 147: 948

    PubMed  CAS  Google Scholar 

  27. Zujecka J, Fawcett J, Schaff M, et al. The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry 1991; 52: 66–8

    Google Scholar 

  28. Goldbloom DS, Kennedy SH. Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. J Clin Psychiatry 1991; 52: 261–2

    PubMed  CAS  Google Scholar 

  29. Piazza LA, Markowitz JC, Kocsis JH, et al. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. Am J Psychiatry 1997; 154: 1757–9

    PubMed  CAS  Google Scholar 

  30. Labbate LA, Grimes J, Hines A, et al. Sexual dysfunction induced by serotonin reuptake antidepressants. J Sex Marital Ther 1998; 24: 3–12

    Article  PubMed  CAS  Google Scholar 

  31. Dorevitch A, Davis H. Fluvoxamine-associated sexual dysfunction. Ann Pharmacother 1994; 28: 872–4

    PubMed  CAS  Google Scholar 

  32. Németh A, Arató M, Treuer T, et al. Treatment of fluvoxamine-induced anorgasmia with a partial drug holiday [letter]. Am J Psychiatry 1996; 153: 1365

    PubMed  Google Scholar 

  33. Mitchell JE, Popkin MK. Antidepressant drug therapy and sexual dysfunction in men: a review. J Clin Psychopharmacol 1983; 3: 76–9

    Article  PubMed  CAS  Google Scholar 

  34. Warnock JK, Burdren JC, Morris DW. Female hypoactive sexual desire disorder due to androgen deficiency: clinical and psychometric issues. Psychopharmacol Bull 1997; 33: 761–5

    PubMed  CAS  Google Scholar 

  35. Barbeau A. L-dopa therapy in Parkinson’s disease: a critical review of nine years experience. J Can Med Assn 1969; 101: 791–800

    Google Scholar 

  36. Goodwin FK. Psychiatric side effects of levodopa in man. JAMA 1971; 218: 1915–20

    Article  PubMed  CAS  Google Scholar 

  37. Sata LS, Shen WW. Neuroleptics and sexual functioning. Integr Psychiatry 1986; 4: 103–5

    Google Scholar 

  38. Labbote LA, Pollack MH. Treatment of fluoxetine-induced sexual dysfunction with bupropion—a case report. Ann Clin Psychiatry 1994; 6: 13–5

    Article  Google Scholar 

  39. Gardner EA, Johnston JA. Bupropion—an antidepressant without sexual psychophysiological action. J Clin Psychopharmacol 1985; 5: 24–9

    Article  PubMed  CAS  Google Scholar 

  40. Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion. J Clin Psychiatry 1993; 54: 459–65

    PubMed  CAS  Google Scholar 

  41. Modell JG, Katholi CR, Modell JD, et al. Comparative sexual side effects of bupropion, fluoxetine, paroxetine and sertraline. Clin Pharmacol Ther 1997; 61: 476–87

    Article  PubMed  CAS  Google Scholar 

  42. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996; 57 Suppl. 2: 53–62

    PubMed  CAS  Google Scholar 

  43. Philipp M, Kohnen R, Benkert O. A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction. Int Clin Psychopharmacol 1993; 7: 149–53

    Article  PubMed  CAS  Google Scholar 

  44. Lauerma H. A case of moclobemide-induced hyperorgasmia. Int Clin Psychopharmacol 1995; 10: 123–4

    Article  PubMed  CAS  Google Scholar 

  45. Shen WW, Park S. The use of monoamine oxidase inhibitors in the treatment of traumatic war neurosis: case report. Milit Med 1983; 148: 430–1

    CAS  Google Scholar 

  46. Nelson JH III, Winter CC. Priapism: evolution of management in 48 patients in a 22-year series. J Urol 1977; 117: 455–8

    PubMed  Google Scholar 

  47. Warner MD, Peabody CA, Whiteford HA. Trazodone and priapism. J Clin Psychiatry 1987; 48: 244–5

    PubMed  CAS  Google Scholar 

  48. Patel AG, Mukherji K, Lee A. Priapism associated with psychotropic drugs. Br J Hosp Med 1996; 55: 315–9

    PubMed  CAS  Google Scholar 

  49. Thompson JW, Ware MR, Blashfield RK. Psychotropic drug medication and priapism: a comprehensive review. J Clin Psychiatry 1990; 51: 430–3

    PubMed  Google Scholar 

  50. Mitchell JE, Popkin MK. Antipsychotic drug therapy and sexual dysfunction in men. Am J Psychiatry 1982; 139: 633–7

    PubMed  CAS  Google Scholar 

  51. Lazarus A. Priapism and psychotropic drug therapy [letter]. J Clin Psychopharmacol 1986; 6: 60–1

    Article  PubMed  CAS  Google Scholar 

  52. Lindenmayer JP Risperidone: efficacy and side effects. J Clin Psychiatry Monogr 1994; 12: 53–60

    Google Scholar 

  53. Nicolson R, McCurley R. Risperidone-associated priapism [letter]. J Clin Psychopharmacol 1997; 17: 133–4

    Article  PubMed  CAS  Google Scholar 

  54. Segraves RT. Overview of sexual dysfunction complicating the treatment of depression. J Clin Psychiatry 1992; 53 Suppl. 10b: 4–10

    Google Scholar 

  55. Shen WW. Female orgasmic inhibition by amoxapine [letter]. Am J Psychiatry 1982; 139: 1220–1

    PubMed  CAS  Google Scholar 

  56. Sovner R. Anorgasmia associated with imipramine but not desipramine: case report. J Clin Psychiatry 1983; 44: 345–6

    PubMed  CAS  Google Scholar 

  57. Reich J. The sexual side effects of an SSRI treated by behavioral methods [letter]. J Ment Nerv Dis 1997; 185: 707

    Article  CAS  Google Scholar 

  58. Benazzi F, Mazzoli M. Fluoxetine-induced sexual dysfunction: a dose-dependent effect? [letter]. Pharmacotherapy 1994; 27: 246

    CAS  Google Scholar 

  59. Rothschild AJ. Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry 1995; 152: 1514–6

    PubMed  CAS  Google Scholar 

  60. Shen WW. The metabolism of psychoactive drugs: a review of enzymatic biotransformation and inhibition. Biol Psychiatry 1997; 141: 814–26

    Article  Google Scholar 

  61. Quirk KC, Einarson TR. Sexual dysfunction and clomipramine. Can J Psychiatry 1982; 27: 228–31

    PubMed  CAS  Google Scholar 

  62. Schubert DSP. Reversal of doxepine-induced hypoactive sexual desire by substitution of nortriptyline. J Sex Edu Ther 1992; 18: 42–4

    Google Scholar 

  63. Shen WW. Pharmacotherapy of schizophrenia: the American current state. Keio J Med (Tokyo) 1994; 43: 192–200

    Article  CAS  Google Scholar 

  64. Yager J. Bethanachol chloride can reverse erectile and ejaculatory dysfunction induced by tricyclic antidepressants and mazindol: case report. J Clin Psychiatry 1986; 47: 210–1

    PubMed  CAS  Google Scholar 

  65. Riley AJ, Riley EJ. Cyproheptadine and antidepressant-induced anorgasmia [letter]. Br J Psychiatry 1986; 148: 217–8

    Article  PubMed  CAS  Google Scholar 

  66. Arnott S, Nutt D. Successful treatment of fluvoxamine-induced anorgasmia with cyproheptadine. Br J Psychiatry 1994; 164: 838–9

    Article  PubMed  CAS  Google Scholar 

  67. Lauerma H. Successful treatment of citalopram-induced anorgasmia by cyproheptadine. Acta Psychiatr Scand 1996; 93: 69–70

    Article  PubMed  CAS  Google Scholar 

  68. Jacobsen FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992; 53: 119–22

    PubMed  CAS  Google Scholar 

  69. Hollender E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blocker. J Clin Psychiatry 1992; 53: 207–9

    Google Scholar 

  70. Shrivastava RK, Shrivastava S, Overweg N, et al. Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors [letter]. J Clin Psychopharmacol 1995; 15: 83–4

    Article  PubMed  CAS  Google Scholar 

  71. Norden MJ. Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors. Depression 1994; 2: 109–12

    Article  Google Scholar 

  72. Gitlin MJ. Treatment of sexual side-effects with dopaminergic agents [letter]. J Clin Psychiatry 1995; 56: 124

    PubMed  CAS  Google Scholar 

  73. Reynolds RD. Sertraline-induced anorgasmia treated with intermittent nefazodone [letter]. J Clin Psychiatry 1997; 58: 89

    Article  PubMed  CAS  Google Scholar 

  74. Nelson EB, Keck PE Jr, McElroy SL. Resolution of fluoxetine-induced sexual dysfunction with the 5-HT3 antagonist granisetron [letter]. J Clin Psychiatry 1997; 58: 496–7

    Article  PubMed  CAS  Google Scholar 

  75. Boolell M, Gepsi-Attee S, Gingell JC, et al. Sildenafil: a novel effective oral therapy for male erectile disorder. Br J Urol 1996; 78: 257–61

    Article  PubMed  CAS  Google Scholar 

  76. NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993; 270: 83–90

    Article  Google Scholar 

  77. Power-Smith P. Beneficial sexual-effects from fluoxetine. Br J Psychiatry 1994; 164: 249–50

    Article  PubMed  CAS  Google Scholar 

  78. Ott BR. Leuprolide treatment of sexual aggression in a patient with dementia and the Kluver-Bucy syndrome. Clin Neuropharmacol 1995; 18: 443–7

    Article  PubMed  CAS  Google Scholar 

  79. Stewart JT, Shin KJ. Paroxetine treatment of sexual inhibition in dementia [letter]. Am J Psychiatry 1997; 154: 1474

    PubMed  CAS  Google Scholar 

  80. Perilstein RD, Lipper S, Friedman LJ. Three cases of paraphilias responsive to fluoxetine treatment. J Clin Psychiatry 1991; 52: 169–70

    PubMed  CAS  Google Scholar 

  81. Kafka MP. Sertraline pharmacotherapy for paraphilias and paraphilia-related disorders: an open trial. Ann Clin Psychiatry 1994; 6: 189–95

    Article  PubMed  CAS  Google Scholar 

  82. Cordoba OA, Chapel JL. Medroxyprogesterone acetate antiandrogen treatment of hypersexuality in a pedophiliac sex offender. Am J Psychiatry 1983; 140: 1036–9

    PubMed  CAS  Google Scholar 

  83. Bartholomew AA. A long-acting phenothiazine as a possible agent to control deviant sexual behavior. Am J Psychiatry 1968; 124: 917–23

    PubMed  CAS  Google Scholar 

  84. Tennent G, Bancroft J, Cass, J. The control of deviant sexual behavior by drugs: A double-blind controlled study of haloperidol, chlorpromazine, and placebo. Arch Sex Beh 1974; 3: 261–71

    Article  CAS  Google Scholar 

  85. Derogatis LR. Etiologic factors in premature ejaculation. Med Aspects Human Sexuality 1980; 14: 1168–76

    Google Scholar 

  86. Bartova D, Bouchal M. Thioridazine treatment of ejaculation praecox. Activitas Nervosa Superior (Praha) 1965; 7: 244–5

    CAS  Google Scholar 

  87. Mellgren A. Treatment of ejaculation praecox with thioridazine. Psychosomatique 1987; 15: 454–60

    Article  Google Scholar 

  88. Bennet D. Treatment of ejaculation praecox with monoamine oxidase inhibitors [letter]. Lancet 1961; 2: 1309

    Article  Google Scholar 

  89. Goodman RE. An assessment of clomipramine (Anafranil) in the treatment of premature ejaculation. J Int Med Res 1980; 8 Suppl. 3: 53–9

    PubMed  Google Scholar 

  90. Girgis SM, El-Haggar S, El-Hermouzy S. A double-blind trial of clomipramine in premature ejaculation. Andrologia 1982; 14: 364–8

    Article  PubMed  CAS  Google Scholar 

  91. Segraves RT, Segraves SK, Maguire E. Clomipramine versus placebo in the treatment of premature ejaculation: a pilot study. J Sex Marital Ther 1983; 19: 198–200

    Article  Google Scholar 

  92. Klug B. Clomipramine in premature ejaculation. Med J Aust 1984; 141: 71

    PubMed  CAS  Google Scholar 

  93. Assalian P. Clomipramine in the treatment of premature ejaculation. J Sex Res 1988; 24: 213–5

    Article  Google Scholar 

  94. Althof SE, Levine SB, Corty EW, et al. A double blind crossover trial of clomipramine for rapid ejaculation in 15 couples. J Clin Psychiatry 1995; 56: 402–7

    PubMed  CAS  Google Scholar 

  95. Segraves RT. Treatment of premature ejaculation with lorazepam [letter]. Am J Psychiatry 1987; 144: 1240

    PubMed  CAS  Google Scholar 

  96. Stratta P, Mancini F, Cupillari M, et al. Fluoxetine in premature ejaculation [letter]. Human Psychopharmacol 1993; 8: 61–2

    Article  Google Scholar 

  97. Forester P, King J. Fluoxetine for premature ejaculation [letter]. Am J Psychiatry 1994; 151: 1523

    Google Scholar 

  98. Kindler S, Dolbert OT, Cohen H, et al. The treatment of comorbid premature ejaculation and panic disorder with fluoxetine. Clin Neuropharmacol 1997; 20: 466–71

    Article  PubMed  CAS  Google Scholar 

  99. Waldinger MD, Hengeveld MW, Zwinderman AH. Paroxetine treatment of premature ejaculation: a double blind, randomized, placebo-controlled study. Am J Psychiatry 1994; 151: 1377–9

    PubMed  CAS  Google Scholar 

  100. Wise TN. Sertraline as a treatment for premature ejaculation [letter]. J Clin Psychiatry 1994; 55: 417

    PubMed  CAS  Google Scholar 

  101. Mendels J, Camera A, Sikes C. Sertraline treatment for premature ejaculation. J Clin Psychopharmacol 1995; 15: 341–6

    Article  PubMed  CAS  Google Scholar 

  102. Burnap DW, Golden JS. Sexual problems in medical practice. J Med Educ 1967; 42: 673–80

    PubMed  CAS  Google Scholar 

  103. Greenblatt DJ, Shadec RI, Koch-Weser J. Psychotropic drug use in the Boston area. Arch Gen Psychiatry 1975; 32: 518–21

    Article  PubMed  CAS  Google Scholar 

  104. Singh H. A case of inhibition of ejaculation as a side effect of Mellaril. Am J Psychiatry 1961; 117: 1041–2

    Google Scholar 

  105. Shen WW, Park S. Thioridazine-induced inhibition of female orgasm. Psychiatr J Univ Ottawa 1982; 7: 249–251

    CAS  Google Scholar 

  106. Wyatt RJ, Fram DH, Buchbinder R, et al. Treatment of intractable narcolepsy with monoamine oxidase inhibitor. N Engl J Med 1971; 285: 987–91

    Article  PubMed  CAS  Google Scholar 

  107. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull 1997; 33: 735–45

    Google Scholar 

  108. Ellison JM, DeLuca P. Fluoxetine induced genital anesthesia relieved by Ginkgo biloba extract [letter]. J Clin Psychiatry 1998; 59: 199–200

    Article  PubMed  CAS  Google Scholar 

  109. Shen WW, Urosovich, Clayton DO. Sildenafil in the treatment of female sexual dysfunction induced by selective serotonin reuptake inhibitors: a case report and a review of the literature. J Reprod Med. In press

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, St Louis University School of Medicine, 1221 South Grand Boulevard, St Louis, Missouri, 63104, USA

    David O. Clayton &  Winston W. Shen

Authors
  1. David O. Clayton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Winston W. Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clayton, D.O., Shen, W.W. Psychotropic Drug-Induced Sexual Function Disorders. Drug-Safety 19, 299–312 (1998). https://doi.org/10.2165/00002018-199819040-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199819040-00005

Keywords

Search

Navigation